A Q&A with Bryan Laffitte, who leads a Novartis team that’s using the tools of genetic medicine to innovate new therapies for neuromuscular and neurodegenerative conditions.

Novartis is proud to share that TIME has recognized Victor Bultó and Thierry Diagana among the most influential people shaping the future of health. Learn more about what drives our honorees.

Leprosy is one of the world’s oldest infectious diseases – yet there are still around 200,000 cases every year¹. As the only supplier of multidrug therapy, in January 2026 Novartis renewed its partnership to provide the medicine via the WHO, protecting vital access to treatment.

Novartis-Harvard team identifies a new type of cell that is key to the disease.

In Wendi Yajnik’s quest to find new technologies that could transform medicine, relationships are priority No. 1.

Novartis is strongly committed in helping and supporting employees impacted by cancer through the program Ensemble – Caring for Colleagues (Ensemble).

Neurological diseases develop out of sight. Novartis neuroscientists are bringing them into the light, using human brain cells grown in the lab.

Dr. Botond Roska says we should keep our eyes on gene therapy.

The best treatment for multifaceted diseases like NASH may be combinations of drugs.